title: Treatment of refractory sarcoidal parotid gland swelling in a previously reported unresponsive case.
abstract: BACKGROUND
  Sarcoidosis is a multisystem granulomatous disease that is seen occasionally in patients with characteristic bilateral parotid gland swelling. Conventional therapy has involved either no treatment because of spontaneous remission or corticosteroids when organ involvement is severe.
  
  
  METHODS
  The authors describe a previously published case report of a patient with sarcoidosis with parotid gland swellings who did not respond to standard therapy. Despite the use of various immunosuppressive agents, the swellings failed to resolve over a three-year period. It was only after a newly recommended agent, infliximab, was used that the patient's condition was treated successfully.
  
  
  CONCLUSIONS
  It is important for dental practitioners to be familiar with manifestations of sarcoidosis, particularly its salivary gland aspects. Inherent in the knowledge of the disease is the therapeutic approach to both routine and recalcitrant
authors.affiliation: Salivary Gland Center, School of Dental and Oral Surgery, Columbia University, New York, NY 10032, USA. LM7@Columbia.edu
authors.forename: Louis
authors.initials: L
authors.lastname: Mandel
authors.forename: Barry
authors.initials: B
authors.lastname: Wolinsky
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Chalom
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D000069285:Infliximab; D010305:Parotid Diseases / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D012507:Sarcoidosis / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab